EndoStim has developed an implantable neuromodulation system for the treatment of severe gastro esophageal reflux disease (GERD).

Recent News

October 28, 2016
New data on EndoStim® therapy for the treatment of gastro-esophageal reflux disease (GERD) presented at United European Gastroenterology Week 2016

May 17, 2016
EndoStim Names Rohan Hoare, Ph.D., as New President and CEO

May 12, 2016
EndoStim Secures $25 Million in Funding to Expand Commercialization Efforts and Conduct a Pivotal U.S. Clinical Trial


Company Info
Country: USA
Industry:    Medtech
Sector: medical technology
Status: Unrealized
Vehicle: Endeavour Medtech Growth LP

Company website

Endeavour Vision Team
Alexander Schmitz
Robert OHolla
© Endeavour Vision SA 2006-2017 Terms & Conditions